Research Advances on the Role of Helicobacter pylori CagA Protein in the Pathogenesis of Gastric Cancer
DOI:
https://doi.org/10.64229/tn6ker71Keywords:
Helicobacter pylori, CagA Protein, Gastric Cancer, PathogenesisAbstract
Helicobacter pylori (Hp) infection is a key environmental factor in the development of gastric cancer, with its virulence factor, the cytotoxin-associated gene A (CagA) protein, playing a central role in the pathogenic process. Extensive research data indicate that in regions with a high incidence of gastric cancer, the infection rate of Hp is significantly higher than in low-incidence areas, and Hp infection shows a clear geographical correlation with the incidence of gastric cancer. Moreover, the occurrence of intestinal metaplasia in Hp-positive patients is far more frequent than in Hp-negative individuals, suggesting that Hp may promote the formation of intestinal metaplasia.
This article systematically reviews recent research advances on the mechanisms by which the CagA protein drives the development and progression of gastric cancer, including interference with host cell signaling pathways, induction of epithelial-mesenchymal transition (EMT), promotion of immune evasion, synergy with environmental carcinogens, and regulation of key metabolic enzymes. As a major virulence factor of H. pylori, CagA can activate signaling networks such as SHP2, PI3K/Akt, MAPK, and Wnt/β-catenin through both phosphorylation-dependent and independent pathways. Current evidence suggests that this disrupts the balance between cell proliferation and apoptosis, although its role in pro-apoptotic effects may be relatively limited.
The aberrant activation of these signaling pathways may ultimately lead to uncontrolled cell proliferation, inhibited apoptosis, genomic instability, and microenvironment remodeling. In-depth investigation of the carcinogenic mechanisms of CagA can provide an important theoretical basis for molecular typing, risk prediction, and targeted intervention of gastric cancer, holding profound significance for its prevention and treatment.
References
[1]IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum. 2012;100B:1-441.
[2]Hatakeyama M. Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis. Cell Host Microbe. 2014;15(3):306-316. doi:10.1016/j.chom.2014.02.008
[3]Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.
[4]Correa P. Human gastric carcinogenesis: a multistep and multifactorial process. Cancer Res. 1992;52(24):6735-6740.
[5]Zeng M, Mao XH, Li JX, et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(10002):1457-1464.
[6]Hatakeyama M. Structure and function of Helicobacter pylori CagA, the first-identified bacterial protein involved in human cancer. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(4):196-219.
[7]Backert S, Tegtmeyer N, Fischer W. Composition, structure and function of the Helicobacter pylori cag pathogenicity island encoded type IV secretion system. Future Microbiol. 2015;10(6):955-965.
[8] Hatakeyama M. Molecular anatomy and pathogenic actions of Helicobacter pylori CagA that underpin gastric carcinogenesis. Cell Mol Immunol. 2020;17(1):50-63. doi:10.1038/s41423-019-0339-5
[9]Saadat I, Higashi H, Obuse C, et al. Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity. Nature. 2007;447(7142):330-333.
[10]Tegtmeyer N, Wessler S, Backert S. Role of the cag-pathogenicity island encoded type IV secretion system in Helicobacter pylori pathogenesis. FEBS J. 2017;284(6):858-878.
[11]Yong X, Tang B, Li BS, et al. Helicobacter pylori virulence factor CagA promotes tumorigenesis of gastric cancer via multiple signaling pathways. Cell Commun Signal. 2020;18(1):1-15.
[12] Wang J, Deng R, Chen S, et al. Helicobacter pylori CagA promotes immune evasion of gastric cancer by upregulating PD-L1 level in exosomes. iScience. 2023;26(12):108414. doi:10.1016/j.isci.2023.108414
[13] Pritchard DM, Crabtree JE. Helicobacter pylori and gastric cancer. Curr Opin Gastroenterol. 2006;22(6):620-625. doi:10.1097/01.mog.0000245539.50765.f6
[14]Toh JWT, Wilson RB. Pathogenesis of Helicobacter pylori infection. Scand J Gastroenterol. 2020;55(8):904-910.
[15]Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27-47.
[16] Chen S, Duan G, Zhang R, Fan Q. Helicobacter pylori cytotoxin-associated gene A protein upregulates α-enolase expression via Src/MEK/ERK pathway: implication for progression of gastric cancer. Int J Oncol. 2014;45(2):764-770. doi:10.3892/ijo.2014.2444
[17]Correa P, Piazuelo MB. The gastric precancerous cascade. J Dig Dis. 2012;13(1):2-9.
[18]Hayashi T, Senda M, Suzuki N, et al. Differential mechanisms for SHP2 binding and activation are exploited by geographically distinct Helicobacter pylori CagA oncoproteins. Cell Rep. 2017;20(12):2876-2890.
[19]Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 2020;69(12):2113-2121.
[20]Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30.
[21]Jones KR, Joo YM, Jang S, et al. Polymorphism in the CagA EPIYA motif impacts development of gastric cancer. J Clin Microbiol. 2009;47(4):959-968.
[22]Sutton P, Boag JM. Status of vaccine research and development for Helicobacter pylori. Vaccine. 2019;37(50):7295-7299.
[23]Akhiani AA, Pappo J, Kabok Z, et al. Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. J Immunol. 2002;169(12):6977-6984.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ronglu Xu, Wenchao Zhang (Author)

This work is licensed under a Creative Commons Attribution 4.0 International License.